Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones

2025.11.20 22:26

I'm PortAI, I can summarize articles.

Inovio Pharmaceuticals Inc. shares fell 2.81% to $1.73 on Thursday, marking the fourth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, which rose 0.28%, and Pfizer, which fell 1.93%. Inovio's stock is 62.47% below its 52-week high. Trading volume was significantly below the 50-day average. The NASDAQ Composite Index and Dow Jones Industrial Average also declined.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Inovio Pharmaceuticals Inc. (INO) slid 2.81% to $1.73 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 2.15% to 22,078.05 and Dow Jones Industrial Average falling 0.84% to 45,752.26. This was the stock's fourth consecutive day of losses. Inovio Pharmaceuticals Inc. closed 62.47% below its 52-week high of $4.61, which the company reached on December 3rd. The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.28% to $203.07, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) fell 1.93% to $24.40. Trading volume (828,613) remained 380,438 below its 50-day average volume of 1.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-20-25 1726ET